Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Matthews, Gail V ^a   Ali, Rachel J ^a   Avihingsanon, Anchalee ^b   Amin, Janaki ^a   Hammond, Rachel ^c   Bowden, Scott ^c   Lewin, Sharon R ^d,e,f   Sasadeusz, Joe ^g   Littlejohn, Margaret ^c   Locarnini, Stephen L ^c   Ruxrungtham, Kiat ^b   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f BURNET INSTITUTE   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; MALE; MIXED INFECTION; NONHUMAN; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY; THAILAND; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THAILAND; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84876017643     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061297     Document Type: Article

References (28)

1. Bodsworth NJ, Cooper DA, Donovan B, (1991) The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. JInfectDis 163: 1138-1140.
2. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926.
3. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, et al. (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140: 132-143.
4. Gane E, Lee SS, Heathcote EJ, Sievert W, Trinh H, et al. (2010) Four Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B (CHB), Preliminary Analysis. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010).Boston.
5. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, et al. (2010) Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 139: 1934-1941.
6. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW, (1994) Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 23: 251-257.
7. Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, et al. (2011) Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int.
8. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, et al. (2009) Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology49: 1151-1157.
9. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, et al. (2009) Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology49: 1141-1150.
10. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, et al. (2011) Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir Ther 16: 199-205.
11. Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, et al. (2012) Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 26: 939-949.
12. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, et al. (2008) A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology48: 1062-1069.
13. Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, et al. (2010) Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther 15: 917-922.
14. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, et al. (2010) Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology51: 1933-1944.
15. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med354: 1001-1010.
16. Lai C, Chien R, Leung N, Chang T, Guan R, et al. (1998) A one-year trial of lamivudine for hepatitis B. New England Journal of Medicine339: 61-68.
17. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med348: 808-816.
18. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, et al. (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology33: 1527-1532.
19. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med352: 2682-2695.
20. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, et al. (2011) Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology53: 1486-1493.
21. Liaw YF, (2003) Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 18: 246-252.
22. Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, et al. (2003) A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 52: 416-419.
23. Miailhes P, Trabaud MA, Pradat P, Lebouche B, Chevallier M, et al. (2007) Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 45: 624-632.
24. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, et al. (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126: 1750-1758.
25. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, et al. (2004) Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol 16: 1213-1218.
26. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, et al. (2011) Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 54: 449-454.
27. Jung YK, Kim JH, Lee YS, Lee HJ, Yoon E, et al. (2010) Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 44: 653-657.
28. Cai W, Xie Q, An B, Wang H, Zhou X, et al. (2010) On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 48: 22-26.